Loading...
Tumor Mutational Burden, Toxicity and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-Regression Analysis
PURPOSE: Tumor mutational burden (TMB) has emerged as a potential predictive biomarker for clinical response to ICI therapy, but whether TMB also predicts toxicity remains unknown. We investigated the relationship between TMB, objective response rate (ORR), overall survival (OS), and toxicity for IC...
Na minha lista:
| Udgivet i: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7501151/ https://ncbi.nlm.nih.gov/pubmed/32586938 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0458 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|